While MTA-cooperative PRMT5 inhibitors are predicted to be the closest winner in the race, issues with MTA metabolism in the surrounding tumor microenvironment questions the actual applicability of an MTA-rich environment in PRMT5 inhibition. The gene discussed is PRMT5; the disease is neoplasm.